News AbbVie’s elagolix shows promise in uterine fibroids treatmen... AbbVie's elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for the pipeline drug, which could become a major earner for the company.
News Takeda's narcolepsy programme gets back on track Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
